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We screened 50 glioblastomas for P53 mutations. Five glioblastomas showed heterozygous mutations, while three were putatively
heterozygous. Six of these eight glioblastomas showed elimination of wild-type P53 mRNA. These results strongly suggest that some
sort of mechanism(s) favouring mutated over wild-type P53 mRNA exists in glioblastoma cells with heterozygous mutations of this
gene.
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A majority of tumour suppressor genes present homozygous
or hemizygous mutations (Sherr, 2004). Intriguingly, in the P53
gene, heterozygous mutations have also been detected. Typical
mutations of this gene are of the missense type, leading to
P53 protein gain of function (Nigro et al, 1989; Dittmer et al, 1993).
However, the effects of at least some heterozygous mutations
cannot be explained only by the gain of P53 function (Park et al,
1994). In case of P53 mutations such as R249S or R273H, at
least three mutated monomers per tetramer appeared to be
required to inactivate the transactivation of MDM2 and p21 CIP1/
WAF1 promoters (Chan et al, 2004). In case of R280T mutations,
heterotetramers consisting even of three mutated and one
wild-type P53 monomer showed partially but not completely
abolished activity compared to P53 homotetramers consisting of
wild-type monomers only (Sun et al, 1993). In this context, the
occurrence of heterozygous mutations of P53 remains enigmatic,
leading to a question of whether mechanisms other than P53
mutations or deletions are involved in the elimination of the
wild-type P53 protein. Several nongenomic mechanisms of protein
elimination or aberration have been described, including
processes operating at the level of transcription (e.g., methylation)
or translation (e.g., miRNA) (Voorhoeve et al, 2006; Watanabe
et al, 2007). We examined whether glioblastoma cells with
heterozygous mutations of P53 contained a mixture of wild-type
and mutated P53 mRNA, or predominantly the mutated P53




The study included 50 cases of glioblastoma, diagnosed at
Department of Pathology, Medical University of Lodz, according
to the World Health Organization criteria for classification of brain
tumours (Louis et al, 2007). The group consisted of 25 females and
25 males, aged from 15 to 76 years (median 59.5).
DNA and RNA isolation
The investigations were performed using snap-frozen tissues
stored at  801. DNA was isolated from tumour tissues and blood
samples from each patient. DNA and RNA were coextracted by
means of Macherey-Nagel DNA/RNA purification kit. RNA
samples were treated with DNAase. RNA and DNA concentrations
were measured spectrophotometrically. In all 100ng of total RNA
was reverse-transcribed into single-stranded cDNA in a final
volume of 40ml containing 50mM DTT, 1.5mg oligo(dT), 0.5mM
dNTP, 40 units RNase inhibitor and 200 units M-MLV reverse
transcriptase (Promega).
Loss of heterozygosity and microsatellite instability
analyses
Loss of heterozygosity (LOH) and microsatellite instability (MSI)
analyses were performed using paired tumour specimens and
corresponding peripheral blood samples, to recognise tumour
samples with minimal contamination by normal cells. The
following LOH and MSI markers were used: D1S2734, D1S197,
D1S162, D1S156, D9S319, D9S319, D9S162, D10S587, D10S1267,
D17S1828, AFM119, BAT25, BAT26, BAT40. Forward primers were
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s50 end fluorescence-labeled. PCR was performed in thermocycling
conditions individually established for each pair of primers. PCR
products were denatured and gel electrophoresis in LiCor
automatic sequencer system was applied to the separation and
analysis of PCR-generated alleles.
P53 DNA and cDNA sequencing
Exons 5–8 of the P53 gene were amplified by PCR as described
before and sequenced using the dideoxy termination method and
SequiTherm Excel DNA Sequencing Kit (Epicentre Technologies)
(Zakrzewska et al, 2005).
The primers used for the PCR amplification of cDNA sequences
were: p53:5 0-GTGCAGCTGTGGGTTGATT-30 (sense) and 50 GC
AGTGCTCGCTTAGTGCTC-30 (antisense); annealing temperature
was 531C. The sequencing primers were: p53 exon 5–8: 50-GC
CATCTACAAGCAGTCACA-30 (sense), and p53 exon 8–5: 50-CCC
TTTCTTGCGGAGATTCT-30 (antisense); annealing temperature
was 551C. LiCor automatic sequencer system was applied to the
separation and analysis of PCR-sequencing products.
To verify the results, a semi-quantitative densitometric analysis
was performed in which wild and mutated band intensity was
estimated, and then compared to a neighbouring band in the same
sequencing lane for reference.
Methylation-specific PCR (MSP)
Sodium bisulphite modification of genomic DNA was performed
using the CpGenome Universal DNA Modification Kit (Chemicon
International, Temecula, CA, USA). CpGenome Universal
Methylated DNA (Chemicon International) was used as a
methylation-positive control for the methylated P53 promoter,
and DNA from peripheral blood leukocytes was used as the control
for unmethylated alleles of P53. The MSP was performed as
previously described (Amatya et al, 2005).
RESULTS
Genomic DNA and cDNA obtained from fifty glioblastoma
samples were sequenced for P53 mutations. Mutations of P53
were detected in 16 cases, eight of these being heterozygous
(showing a weak mutated band or a mutated band as strong as the
wild band; Figure 1B). Five of these eight cases were indeed
confirmed as heterozygous when LOH and MSI analyses showed
no or negligible contamination of the tested samples by normal
cells (cases 1–5, Table 1; Figure 1A). In three additional cases (6–
8, Table 1), sequencing results suggested heterozygous mutations
of P53. However, we could not exclude a possible contamination of
the tumour specimens with normal cells in this instance because
no LOH/MSI was detected in them. We defined these cases as
presenting putative heterozygous mutations of P53. In six cases
(including heterozygous as well as putative heterozygous muta-
tions), cDNA sequencing revealed a decreased amount, or lack of,
the wild (nonmutated) template when compared to the genomic
DNA sequencing (cases 1–4, 6–7, Table 1; Figure 1C). A
densitometric analysis of the wild and mutated bands confirmed










Figure 1 Molecular analyses of glioblastomas. (A) example of LOH analysis showing a minimal contamination of the tumour sample with the normal cells
(case 4; only a trace of the lost allele is observed in the tumour sample). The lost allele is marked with an arrow. (B, C) P53-sequencing results. The mutated
nucleotide (p53 Exon 8; codon 273; CGT4TGT; Arg4Cys) is marked with arrows. (B) genomic DNA sequencing (case 3): C and T nucleotides are both
detected, representing a heterozygous mutation. (C) cDNA sequencing (case 3): no wildtype, only mutated mRNA is detected. (D) MSP result representing
a lack of P53 promoter methylation (case 3). T, tumour sample; N, a corresponding normal tissue (blood);  , negative control; þ, positive control; M,
methylated; UM, unmethylated.
Table 1 DNA vs cDNA sequencing in glioblastomas showing P53 mutations
Case No Mutation DNA sequencing cDNA sequencing LOH and/or MSI analysis MS-PCR
Heterozygous mutations
1 273 Arg-His ex8 Domination of normal template Only mutated template visible Cells without MSI not detected UM
2 234 Tyr-His ex7 Domination of normal template Only mutated template visible Cells without MSI not detected UM
3 273 Arg-Cys ex8 Domination of normal template Only mutated template visible Cells without LOH not detected UM
4 175 Arg-His ex5 Domination of normal template Domination of mutated template Minimal contamination with cells
without LOH
M
5 282 Arg-Trp ex8 Domination of normal template Domination of normal template Cells without LOH not detected M
Putative heterozygous mutations
6 190 Pro-Ser ex6 Mutated and wild type template
equally presented
Only mutated template visible No LOH, no MSI detectable UM
7 237 Met-Ile ex7 Domination of normal template Only mutated template visible No LOH, no MSI detectable M
8 273 Arg-His ex8 Domination of normal template Domination of normal template No LOH, no MSI detectable UM
LOH¼Loss of heterozygosity; M¼methylated; MIS¼microsatellite instability; MS-PCR¼methylation-specific PCR; UM¼unmethylated.
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sMS-PCR revealed P53 promoter methylation (Figure 1D) in only
three cases. One had a heterozygous mutation, while another had a
putative heterozygous mutation of the P53. However, in both of
these cases no wild-type cDNA template was detected (case 4
and 7). The third case also presented a heterozygous mutation of
P53 – but without any decrease in the amount of wild-type cDNA
template – as shown by cDNA vs genomic DNA sequencing (case 5,
Table 1).
DISCUSSION
Heterozygous mutations of P53 have been widely described
(Dittmer et al, 1993). In this study we show that a majority of
glioblastomas presenting heterozygous mutations of P53 gene
presented no wild-type P53 mRNA. These results strongly suggest
that glioblastoma cells may have the ability to develop a
mechanism(s) which would allow for either (1) the silencing of
wild-type P53 transcription, (2) the degradation of wild-type
P53 mRNA, or (3) the selective overproduction of mutated P53
mRNA. Moreover, our results show that heterozygous mutations of
P53 gene, elimination of wild-type P53 mRNA, or selective
production of mutated mRNA can occur during glioblastoma
tumorigenesis. An extremely important question thus arises – that
is, ‘what mechanism(s) is (are) responsible for favouring the
mutated P53 mRNA over the wild-type ones?’
A methylation of DNA regulatory elements – mainly promoters,
is one of the mechanisms of tumour suppressor genes silencing
(Watanabe et al, 2007). It was shown that a similar proportion of
gliomas with and without P53 mutation present P53 promoter
methylation (Amatya et al, 2005). Indeed, the lack of wild-type
mRNA – despite the presence of wild-type DNA observed by us,
could be explained by a selective methylation of DNA regulatory
element of nonmutated P53 allele. The primers we used in
methylation-specific PCR have already been successfully used by
the Ohgaki group in analysing P53 promoter methylation in
gliomas (Amatya et al, 2005). Nevertheless, we observed that no
P53 promoter methylation was detectable with this set of primers
in the majority of cases analysed in this study. Collectively, these
results suggest that identification of mechanism(s) responsible for
the elimination of wild-type P53 mRNA requires more research.
Obviously, the elimination of wild-type P53 may have resulted
from a mechanism other than epigenetic changes of P53 DNA
regulatory elements. Nonetheless, uncovering of this mechanism
can be very important for the development of new anti-tumour
therapeutics.
In conclusion, we show in this article that glioblastomas
presenting heterozygous mutations of P53 employ some sort of
mechanism(s) to positively select mutated P53 mRNA. We offer a
relatively easy procedure for determining whether similar situa-
tions also occur in other cancers. The precise mechanism(s) for
favouring the mutated type of P53 mRNA – however, still remains
to be discovered.
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